Medindia

X

Common Diabetes Drug Corrects Mitochondrial Metabolism in Li-Fraumeni Syndrome

by Dr. Trupti Shirole on  November 24, 2016 at 12:35 AM Cancer News   - G J E 4
Li-Fraumeni syndrome is an inherited cancer disorder caused by mutations in the tumor suppressing protein p53. Individuals with Li-Fraumeni syndrome are at an increased risk for a number of cancers, including breast and bone cancer.
 Common Diabetes Drug Corrects Mitochondrial Metabolism in Li-Fraumeni Syndrome
Common Diabetes Drug Corrects Mitochondrial Metabolism in Li-Fraumeni Syndrome
Advertisement

Mutations in the protein p53 have also been linked to increased mitochondrial metabolism. It is not clear whether targeting these metabolic changes can effectively reduce the risk of cancer associated with p53 mutations.

‘Metformin can ameliorate abnormal mitochondrial metabolism and may be a potential strategy for tumor prevention in Li-Fraumeni syndrome.’
Advertisement
In the JCI, research led by Paul Hwang at the National Heart, Lung, and Blood Institute discovered that treatment with the commonly-prescribed diabetes medication metformin treatment blocked increases in mitochondrial metabolism in a mouse model of Li-Fraumeni syndrome, leading to a lower rate of tumor formation and increased survival time.

Furthermore, in a pilot study involving Li-Fraumeni patients, metformin treatment produced a similar inhibition of mitochondrial metabolism and activated of anti-proliferation signaling.

The finding that this FDA-approved drug can ameliorate abnormal mitochondrial metabolism suggests that it may be a potential strategy for tumor prevention in Li-Fraumeni syndrome.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All